Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of OASMIA PHARMACEUT. SK-,10
Analyst Grade Summary
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
1
0
0
0
No Price
Closing Price XSTO 29.04.2026:
0,08 SEK
29.04.2026 15:29
Current Prices from OASMIA PHARMACEUT. SK-,10
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ STOCKHOLM AB
VIVE.ST
SEK
29.04.2026 15:29
0,08 SEK
-0,001 SEK
-1,22 %
Share Float & Liquidity
Free Float94,30 %
Shares Float494,61 M
Shares Outstanding524,5 M
Company Profile for OASMIA PHARMACEUT. SK-,10 Share
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
